A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity.

A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity.

The HIV vaccine strategy that, to date, generated immune protection consisted of a prime-boost regimen using a canarypox vector and an HIV envelope protein with alum, as shown in the RV144 trial. Since the efficacy was weak, and previous HIV vaccine trials designed to generate antibody responses fai...

Full description

Bibliographic Details
Main Authors: Laura Pattacini, Gregory J Mize, Jessica B Graham, Tayler R Fluharty, Tisha M Graham, Karen Lingnau, Benjamin Wizel, Beatriz Perdiguero, Mariano Esteban, Giuseppe Pantaleo, Mingchao Shen, Gregory A Spies, M Juliana McElrath, Jennifer M Lund
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3405041?pdf=render

Internet

http://europepmc.org/articles/PMC3405041?pdf=render

Similar Items